{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T15:13:27Z","timestamp":1791213207352,"version":"4.1.0"},"reference-count":46,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2007,6,26]],"date-time":"2007-06-26T00:00:00Z","timestamp":1182816000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intl Journal of Cancer"],"published-print":{"date-parts":[[2007,10,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Copy number alterations of the epidermal growth factor receptor (<jats:italic>EGFR<\/jats:italic>) gene have been extensively analyzed in different cancers, but no data are available for primary malignant melanoma. The aim of the present study was to simultaneously investigate the <jats:italic>EGFR<\/jats:italic> gene and chromosome 7 copy number alterations in 81 cutaneous malignant melanomas by interphase FISH and correlate the data with clinicopathological parameters of patients. <jats:italic>EGFR<\/jats:italic> mRNA levels were detected by Affymetrix GeneChip Human Genome U133 Plus 2.0 expression arrays for 16 lesions. Both increased gene dosage and chromosome 7 alterations were found in 70% of tumors. Extra <jats:italic>EGFR<\/jats:italic> copies were detected in an additional 10% of samples. Polysomy 7 was associated with <jats:italic>EGFR<\/jats:italic> gene amplification. Significant correlation was found between <jats:italic>EGFR<\/jats:italic> alterations and histological subtypes, tumor thickness, ulceration and metastases formation. Amplification was significantly higher in lesions that developed metastases within 2 years after surgical excision of the primary tumor. Gene copy alterations were associated with elevated mRNA expression in 77% of lesions when compared to tumors with disomic <jats:italic>EGFR<\/jats:italic> status, the correlation was not directly proportional to gene copy number. Associations between protein expression and mRNA levels were even less prominent. In conclusion, our study indicates that amplification of the <jats:italic>EGFR<\/jats:italic> gene and polysomy 7 are frequent alterations in primary melanomas and are associated with bad prognosis. Further studies are required to clarify whether melanoma patients with <jats:italic>EGFR<\/jats:italic> alterations can benefit from anti\u2010EGFR therapy. \u00a9 2007 Wiley\u2010Liss, Inc.<\/jats:p>","DOI":"10.1002\/ijc.22928","type":"journal-article","created":{"date-parts":[[2007,6,26]],"date-time":"2007-06-26T14:48:26Z","timestamp":1182869306000},"page":"1729-1737","source":"Crossref","is-referenced-by-count":77,"title":["EGFR gene copy number alterations in primary cutaneous malignant melanomas are associated with poor prognosis"],"prefix":"10.1002","volume":"121","author":[{"given":"Zsuzsa","family":"R\u00e1kosy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"V\u00edzkeleti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Szilvia","family":"Ecsedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zolt\u00e1n","family":"Vok\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1gnes","family":"B\u00e9g\u00e1ny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e1rk","family":"Barok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsuzsa","family":"Krekk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f3nika","family":"Gallai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zolt\u00e1n","family":"Szentirmay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00f3za","family":"\u00c1d\u00e1ny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margit","family":"Bal\u00e1zs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,8,14]]},"reference":[{"key":"e_1_2_5_2_2","first-page":"4","article-title":"Targeting the epidermal growth factor receptor (EGFR)\u2013a new therapeutic option in oncology?","volume":"136","author":"Mamot C","year":"2006","journal-title":"Swiss Med Wkly"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1677\/erc.0.0080083"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2005.06.012"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(06)70693-3"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21831"},{"key":"e_1_2_5_7_2","first-page":"1579","article-title":"Clinical trial design and end points for epidermal growth factor receptor\u2010targeted therapies: implications for drug development and practice","volume":"9","author":"Arteaga CL","year":"2003","journal-title":"Clin Cancer Res"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2006.02.004"},{"key":"e_1_2_5_9_2","first-page":"E101","article-title":"Usefulness of predictive tests for cancer treatment","volume":"93","author":"Rosell R","year":"2006","journal-title":"Bull Cancer"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01534687"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1206449"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12616793"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-0960.1999.00310.x"},{"key":"e_1_2_5_14_2","first-page":"1759","article-title":"Intertumoral heterogeneity of receptor\u2010tyrosine kinases expression in human melanoma cell lines with different metastatic capabilities","volume":"14","author":"Gutman M","year":"1994","journal-title":"Anticancer Res"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0625.1995.tb00218.x"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.2003.12522.x"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0022-202X.2004.22732.x"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1208125"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.neo.7900156"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199005243222107"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21372"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-4608(98)00159-9"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2004.03.018"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910460322"},{"key":"e_1_2_5_25_2","first-page":"2193","article-title":"Suppression of spontaneous melanoma metastasis in scid mice with an antibody to the epidermal growth factor receptor","volume":"51","author":"Mueller BM","year":"1991","journal-title":"Cancer Res"},{"key":"e_1_2_5_26_2","first-page":"708","article-title":"[Expression of tumor metastasis suppressor gene KAI1\/CD82 in human cancer cell lines with different metastasis potential]","volume":"79","author":"Li S","year":"1999","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.2741\/1927"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/51.5.1417"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.a.20165"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.990200110"},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.a.20374"},{"key":"e_1_2_5_32_2","first-page":"3","article-title":"Anti\u2010EGFR therapy update: clinical experience and adverse event insights","volume":"20","author":"Harari PM","year":"2006","journal-title":"Oncology (Williston. Park)"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.3800438"},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/bth280"},{"key":"e_1_2_5_35_2","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2002-3-7-research0034"},{"key":"e_1_2_5_36_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.11-6-602"},{"key":"e_1_2_5_37_2","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/j.0022-202X.2005.23772.x","article-title":"Constitutive expression of epidermal growth factor receptors on normal human melanocytes","volume":"125","author":"Mirmohammadsadegh A","year":"2005","journal-title":"J Invest Dermatol"},{"key":"e_1_2_5_38_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-007-0742-0"},{"key":"e_1_2_5_39_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19950315)75:6<1228::AID-CNCR2820750604>3.0.CO;2-T"},{"key":"e_1_2_5_40_2","first-page":"43","article-title":"Cytogenetic studies of human malignant melanoma cell lines","volume":"39","author":"Yin M","year":"1992","journal-title":"Bull Tokyo Med Dent Univ"},{"key":"e_1_2_5_41_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20909"},{"key":"e_1_2_5_42_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.21454"},{"key":"e_1_2_5_43_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2559.2005.02252.x"},{"key":"e_1_2_5_44_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.07.2587"},{"key":"e_1_2_5_45_2","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.5.11.3299"},{"key":"e_1_2_5_46_2","first-page":"335","article-title":"An unexpected inverse correlation between soluble epidermal growth factor receptor and interleukin\u20106 in metastatic malignant melanoma patients","volume":"16","author":"Mouawad R","year":"2006","journal-title":"Melanoma Res"},{"key":"e_1_2_5_47_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dji112"}],"container-title":["International Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fijc.22928","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.22928","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T05:28:10Z","timestamp":1700026090000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.22928"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8,14]]},"references-count":46,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2007,10,15]]}},"alternative-id":["10.1002\/ijc.22928"],"URL":"https:\/\/doi.org\/10.1002\/ijc.22928","archive":["Portico"],"relation":{},"ISSN":["0020-7136","1097-0215"],"issn-type":[{"value":"0020-7136","type":"print"},{"value":"1097-0215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,8,14]]}}}